menu
    • menu
    [{"orgOrder":0,"company":"Ardelyx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Tenapanor Hydrochloride","moa":"Sodium\/hydrogen exchanger 3","graph1":"Gastroenterology","graph2":"Approved","graph3":"Ardelyx","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ardelyx \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ardelyx \/ Not Applicable"},{"orgOrder":0,"company":"Ardelyx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Tenapanor Hydrochloride","moa":"Sodium\/hydrogen exchanger 3","graph1":"Gastroenterology","graph2":"Approved","graph3":"Ardelyx","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ardelyx \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ardelyx \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Tenapanor Hydrochloride

    Menu

    Tenapanor Hydrochloride

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Ardelyx

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed

                            Ardelyx

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tenapanor Hydrochloride

                            Therapeutic Area : Gastroenterology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Ardelyx Announces Additional Data Supporting the Efficacy and Safety of First-In-Class IBSRELA® (tenapanor) f...

                            Details : IBSRELA (tenapanor) is a locally acting inhibitor of the sodium/hydrogen exchanger 3 (NHE3), an antiporter expressed on the apical surface of the small intestine and colon primarily responsible for the absorption of dietary sodium.

                            Brand Name : Ibsrela

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 17, 2022

                            Lead Product(s) : Tenapanor Hydrochloride

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Ardelyx

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed

                            Ardelyx

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tenapanor Hydrochloride

                            Therapeutic Area : Gastroenterology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Ardelyx Announces US Launch of IBSRELA®, a New First-in-Class Treatment for IBS-C in Adults

                            Details : IBSRELA®(tenapanor) is the first and only NHE3 Inhibitor FDA approved for the treatment of IBS-C in adults, reported 41% improvement in quality of life score from baseline to end of treatment, and vast majority of patients reported satisfaction with tre...

                            Brand Name : Ibsrela

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            April 04, 2022

                            Lead Product(s) : Tenapanor Hydrochloride

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth